冻干重组人脑利钠肽治疗充血性心力衰竭疗效观察

目的 探讨冻干重组人脑利钠肽治疗充血性心力衰竭的临床疗效和安全性.方法 选择120例充血性心力衰竭患者,按照随机数字分组法分为两组,观察组58例患者采用冻干重组人脑利钠肽进行治疗,对照组62例患者采用硝普钠进行治疗,比较两组患者的临床疗效、超声心动图指标、血流动力学指标的变化情况以及不良反应的发生情况.结果 治疗后,观察组总有效率为91.37％,明显高于对照组（x2=4.23,P＜0.05）,观察组治疗后的LVEF、氨基末端脑钠肽前体水平分别为（59.0±8.2）％和（535.4±123.8） ng/L,其改善程度较对照组更为明显（P＜0.05）,两组不良反应的发生率基本相当（P＞0.05）.结论 冻干重组人脑利钠肽在治疗充血性心力衰竭具有十分显著的疗效,其安全可靠.

Clinical efficacy of lyophilized recombinant human brain natriuretic peptide in the treatment of patients with congestive heart failure

Objective To investigate the clinical efficacy and safety of lyophilized recombinant human brain natriuretic peptide（rhBNP） in the treatment of patients with congestive heart failure （CHF）. Methods 120 CHF patients were randomly divided into two groups. 58 cases in the observation group were given lyophilized rhBNP, and 62 patients in the control group were given sodium nitroprusside. The clinical effect, changes of echocardiographic in- dicators and hemodynamic parameters, adverse reactions were observed. Results After treatment, the total effective rate of the observation group was 91.37%, which was significantly higher than that of the control group（ X2 = 4.23, P 〈 0. 05 ）. The LVEF and NT-proBNP levels in observation group were （59.0 ± 8.2）% and （535.4 ± 123.8）ng/L, which had higher improvement than control group （ P 〈 0.05 ）. The incidence rate of adverse reactions between the two groups had no significant difference （ P 〉 0.05 ）. Conclusion Lyophilized rhBNP in the treatment of CHF has significant effect, and it is worthy of clinical application and promotion.